Swipe om te navigeren naar een ander artikel
To describe the psychometric properties and identify the minimally important difference (MID) of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument. Chronic HCV infection and associated treatments negatively affect PROs of function and well-being.
In a phase 2 trial, HCV-infected patients received direct-acting antivirals (DAAs) for 12 weeks with peg-interferon/ribavirin (peg-IFN/RBV) for 48 weeks, or placebo plus peg-IFN/RBV. The HCV-PRO total score, SF-36 PCS and MCS scores, EQ-5D-3L, and EQ VAS were measured at baseline, week 8, end of DAA treatment (EODT), end of peg-IFN/RBV treatment (EOT), and posttreatment week 24 (SVR24). Convergent validity of the HCV-PRO was assessed by Pearson’s correlation coefficients. Discriminant validity was assessed by analyzing mean HCV-PRO total scores by EQ-5D anxiety/depression and pain/discomfort domain scores (none vs. some) and presence/absence of depression or fatigue adverse events. MID was identified through effect size (ES) and receiver-operating characteristic (ROC) curve analyses (HCV-PRO response vs. SF-36 PCS/MCS and EQ VAS MID thresholds).
In 74 patients (22 % female; 81 % White; 51 % ≥50 years), correlations (0.64–0.96) between HCV-PRO total scores, SF-36 PCS/MCS scores, and EQ VAS scores at all time points supported convergent validity. HCV-PRO total scores were reduced to 10–30 points in patients impaired by depression, pain, or fatigue symptoms. Impact of peg-IFN/RBV regimen on HCV-PRO ES increased over time (EODT −0.76; EOT −0.93). ES and ROC curve analyses indicated an MID of −10 points.
The HCV-PRO was valid and responsive in the population studied. An MID of −10 points represented a threshold of clinical significance for the HCV-PRO.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
World Health Organization. (2012). Hepatitis C. Fact Sheet N°164. Geneva, Switzerland: World Health Organization. Accessed September 17, 2012, from http://www.who.int/mediacentre/factsheets/fs164/en/.
Smith, B. D., Morgan, R. L., Beckett, G. A., Centers for Disease Control and Prevention, et al. (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep, 61(RR-4), 1–36. PubMed
Bergmann, J. F., Vrolijk, J. M., van der Schaar, P., et al. (2007). Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver International, 27, 1217–1225. PubMed
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post-hoc analyses of data from the ADVANCE trial. Journal of Hepatology, 56(Suppl 2), S462–S463. CrossRef
Younossi, Z. M., Aggarwal, J., Martin, M., et al. (2012). Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: Post-hoc analyses of data from the ADVANCE trial. Gastroenterology, 142(Suppl 5), S-955. [Abstract Sa1048].
Gralnek, I. M., Hays, R. D., Kilbourne, A., et al. (2000). Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease–the LDQOL 1.0. American Journal of Gastroenterology, 95, 3552–3565. PubMed
Anderson R. T., Baran R. W., Dietz B., Kallwitz E., Erickson P., Revicki D. A. (2013). Development and psychometric evaluation of the hepatitis C virus-patient reported outcomes (HCV-PRO) instrument. Qual Life Res, in review.
Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74, 65132–65133.
Gaultier, I., Cohen, D. E., Bhathena, A., et al. (2011). The effect of IL28B polymorphism on virologic response to treatment with pegylated interferon alpha-2a and RBV (SOC) added to ABT-450/ritonavir (ABT-450/r), ABT-333, or ABT-072. Journal of Hepatology, 54(Suppl 1), S523. CrossRef
Ware, J. E, Jr, Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln, RI: QualityMetric Incorporated.
The EuroQol Group. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16, 199–208. CrossRef
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory (3rd ed.). New York, NY: McGraw-Hill Inc.
- Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial
Roger T. Anderson
Robert W. Baran
Dennis A. Revicki
- Springer International Publishing